5,6-Epoxycholesterol Isomers Induce Oxiapoptophagy in Myeloma Cells

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is an incurable plasma cell cancer with high relapse rates due to drug resistance.
• Altered cholesterol metabolism is a known characteristic of MM.
• Investigating cholesterol derivatives for anti-cancer properties is a promising therapeutic avenue.

Purpose of the Study:

• To evaluate the anti-myeloma activity of 5,6 α-epoxycholesterol (EC) and 5,6 β-EC isomers.
• To understand the mechanism of action of these cholesterol derivatives in MM cells.
• To explore the potential synergistic effects of combining 5,6 α-EC and 5,6 β-EC.

Main Methods:

• In vitro viability assays using JJN3 and U266 human myeloma cell lines (HMCLs).
• Ex vivo testing on CD138+ malignant cells sorted from MM patients.
• Analysis of cell death mechanisms, including oxidative stress, apoptosis, and autophagy.

Main Results:

• Both 5,6 α-EC and 5,6 β-EC demonstrated significant anti-tumor activity against MM cell lines and patient cells.
• The EC isomers induced oxiapoptophagy, a combined process of oxidative stress, apoptosis, and autophagy.
• A synergistic anti-myeloma effect was observed when 5,6 α-EC and 5,6 β-EC were used in combination.

Conclusions:

• 5,6 α-EC and 5,6 β-EC exhibit potent anti-myeloma activity through a novel oxiapoptophagy mechanism.
• These cholesterol derivatives show promise as novel therapeutic agents for multiple myeloma.
• The synergistic interaction between the two isomers warrants further investigation for clinical application in MM treatment.